Company news
Marvel Biosciences Corp (TSXV:MRVL) news
Marvel Biosciences Corp news releases on 6ix. Latest, Oct 6, 2026: Marvel Biosciences Signs Letter of Intent with Novatech for Phase 1 Trial of MB-204…
Press releases & updates
Marvel Biosciences Signs Letter of Intent with Novatech for Phase 1 Trial of MB-204 and Provides Corporate Update
October 6, 2026
Marvel Biosciences Announces Closing of Private Placement For Up To $3.0 Million
September 29, 2026
Marvel Biosciences Provides Update on Private Placement for up to $3.0 Million
September 17, 2026
Marvel Biosciences Announces Extension to Closing Date of Private Placement
September 9, 2026
Marvel Biosciences Expands Private Placement to Quebec
August 19, 2026
Marvel Biosciences Reports Positive Preclinical Data Demonstrating MB-204 Reverses Behavioural and Cognitive Deficits in a Mouse Model of Fragile X
August 5, 2026
Marvel Biosciences Announces Private Placement for up to $3.0 Million
July 16, 2026
New Autism Research to be Presented at European Purine Scientific Meeting
June 26, 2026
Marvel Biosciences Receives Notice of Allowance for Australian Patent Application Covering Composition of Matter for its Lead Therapeutic Candidate MB-204
June 8, 2026
Marvel Biosciences to Participate and Present at the 2nd Neuroscience Innovation Partnering and Licensing Summit
April 23, 2026
Marvel Biosciences Announces Closing of Convertible Debenture Offering
April 17, 2026
Marvel Biosciences Identifies Liquid Formulations for Neurodevelopmental Disorders
April 16, 2026
Marvel Biosciences Announces an Amendment to the Conversion Price for Marvel's Proposed Convertible Debenture Offering
April 13, 2026
Marvel Biosciences Announces Proposed Convertible Debenture Offering
April 8, 2026
Marvel Biosciences Secures Financial and Strategic Investment with 5 Horizon Ventures
April 7, 2026
Marvel Biosciences Secures Alberta Innovates Funding to Support the Phase I Testing of MB-204
March 30, 2026
Marvel Biosciences Selects Novotech as CRO for Its Phase I Clinical Trial of MB-204
March 25, 2026
Marvel Biosciences Receives Notice of Allowance for US Patent Application Covering Composition of Matter for Its Lead Therapeutic Candidate MB-204
March 18, 2026
Marvel Biosciences Sponsors Scientific Meeting on Purines
March 4, 2026
Marvel Biosciences Secures Funding to Develop Child-Friendly Liquid Formulation for Neurodevelopmental Disorders
February 18, 2026
Marvel Biosciences Receives Japanese Patent Covering Composition of Matter for Its Lead Therapeutic Candidate MB-204
February 3, 2026
Toronto Stock Exchange, Marvel Biosciences Corp., The View from the C-Suite
December 22, 2025
Marvel Biosciences Announces Grant of Deferred Share Units
November 10, 2025
Marvel Biosciences Announces Acceleration of Warrant Expiry Date
October 3, 2025
Marvel Biosciences Granted Chinese Patent for Lead Therapeutic Candidate MB-204
August 18, 2025
Marvel Biosciences Announces Closing of Private Placement
May 12, 2025
Marvel Biosciences Announces Closing of Second Tranche of Private Placement
May 2, 2025
Marvel Announces the Second of Two Final Data Sets from Rett Syndrome Study: MB-204 Significantly Outperforms Trofinetide Following Cessation of Drug Treatment
April 30, 2025
Marvel Biosciences to Give Oral Presentation at The Annual IRSF Rett Syndrome Scientific Meeting
April 16, 2025
Marvel Biosciences Selected to Present Alzheimer's Research at the 2025 Alzheimer's Association International Conference
April 14, 2025
Marvel Biosciences Announces Private Placement
March 28, 2025
Marvel to File for Orphan Drug Designation with The U.S. FDA for MB-204 as a Treatment for Rett Syndrome
March 17, 2025
Marvel Announces First of Two Final Data Sets from Rett Syndrome Study: MB-204 Significantly Outperforms Trofinetide
March 13, 2025
Marvel Presenting at the 2025 Bloom Burton & Co. Conference
March 11, 2025
Marvel Biosciences Announces Notice of Allowance of Composition of Matter Patent for Its Lead Molecule MB-204 in China
January 16, 2025
Marvel Biosciences Announces Private Placement for up to $2.5 Million
January 7, 2025
Marvel Biosciences Announces Promising New Data from Rett Syndrome Study and Plans to Discuss Orphan and Rare Disease Status with the FDA
November 26, 2024
Marvel Biosciences Secures $300,000 Grant to Advance Groundbreaking Alzheimer's Research
November 21, 2024
Marvel Biosciences Announces MB204 Outperforms Approved Drug Trofinetide in a Preclinical Model of Rett Syndrome
November 7, 2024
Marvel Biosciences Shares Positive Results of MB204 in the Oprm1 Model of Autism
October 10, 2024
Marvel Announces Its Collaboration with FRAXA to Test MB204 In Pre-Clinical Models of Fragile X Syndrome
August 13, 2024
Marvel Biosciences Announces Stock Option Grants
July 25, 2024
Marvel Announces an Extension to Its Collaboration with The iBraiN Institute to Test MB204 In a Pre-Clinical Model of Rett Syndrome
July 24, 2024
Marvel Biosciences Closes Private Placement
July 19, 2024
Marvel Highlights New Published Research of Its SAB Member Professor David Blum
July 9, 2024
Marvel Biosciences Announces Private Placement Update
June 21, 2024
Marvel Biosciences Announces Positive Interim Results on Tau Phosphorylation with MB-204
March 25, 2024
Marvel Biosciences Announces Positive Interim Results for Autism Treatment with MB-204
March 12, 2024
Marvel Biosciences Announces Testing MB-204 on Autism by French University
February 20, 2024
Marvel Biosciences Announces Closing of Non-Brokered Private Placement
January 19, 2024